Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?

Feb 21, 2025Internal medicine journal

Can incretin drugs replace weight-loss surgery for treating obesity?

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Bariatric surgery has shown durability of weight loss for over 10 years.

Obesity is linked to increased risks of various diseases, reduced quality of life, and shorter life expectancy.
Bariatric surgery significantly improves cardiometabolic risk factors, including blood sugar levels and hypertension.
Patients who undergo bariatric surgery have lower rates of all-cause mortality and cardiovascular events compared to those who do not have surgery.
Newer therapies like semaglutide and tirzepatide show strong effectiveness in weight loss and also improve outcomes for type 2 diabetes and cardiovascular health.
Emerging evidence suggests that incretin agonist therapies may influence the need for bariatric surgery in the future.

AI simplified

The prevalence of obesity continues to increase worldwide. Obesity is associated with an increased risk of cardiometabolic and other diseases, reduced quality of life and shortened life expectancy. Highly effective therapies are required to achieve meaningful and sustained weight reduction to prevent, slow or reverse disease associated with obesity. Bariatric surgery is a highly effective intervention to induce weight loss, with observational data demonstrating durability of weight loss over 10 or more years. In addition, bariatric surgery improves cardiometabolic risk factors, including hyperglycaemia and type 2 diabetes, hypertension and dyslipidaemia. Observational data have shown a reduction in all-cause mortality, cardiovascular events and mortality and a reduction in cancer risk and mortality in patients who have undergone bariatric surgery compared to matched patients who did not have surgery. The emergence of newer incretin agonists, particularly semaglutide and tirzepatide, have demonstrated remarkable efficacy in inducing and maintaining weight loss with ongoing use. As for bariatric surgery, incretin agonist therapies also improve type 2 diabetes outcomes, cardiovascular mortality and other obesity-related complications, with new evidence emerging and long-term outcome data awaited. This perspective compares bariatric surgery and incretin agonist therapy, assessing their relative efficacies in weight reduction, impact on obesity-related complications, their respective risk profiles and considerations of cost-effectiveness and equity of access. These comparisons seek to evaluate whether these increasingly popular medications could make bariatric surgery a thing of the past.

Full Text

Full text is available at the source.

View full text ↗

Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief